Molecular genetics of experimental hypertension and the metabolic syndrome: From gene pathways to new therapies

Hypertension

Volumn 49, Issue 5, 2007, Pages 941-952

  Pravenec, Michal ^a   Kurtz, Theodore W ^b  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin II type 1 receptor blockers; Genetics; Hypertension; Inbred SHR; Metabolic syndrome X; Peroxisome proliferator activated receptors; Rats

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CD36 ANTIGEN; EPROSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SODIUM CHLORIDE; STEROID 11BETA MONOOXYGENASE; TELMISARTAN; VALSARTAN;

BLOOD PRESSURE; DRUG ACTIVITY; GENE EXPRESSION; GENE IDENTIFICATION; GENE MAPPING; GENE MUTATION; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC VARIABILITY; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; REVIEW; ANIMAL; GENETICS; MUTATION;

ANIMALS; ANTIGENS, CD36; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; MUTATION; QUANTITATIVE TRAIT LOCI; STEROID 11-BETA-HYDROXYLASE;

EID: 34247867956     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.086900     Document Type: Review

References (105)

1. Ganten D. Role of animal models in hypertension research. Hypertension. 1987;9(supp I):I-2.
2. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Japn Circ J. 1963;27:282-293.
3. Dahl LK, Heine M, Tassinari L. Role of genetic factors in susceptibility to experimental hypertension due to chronic excess salt ingestion. Nature. 1962;194:480-482.
4. Rapp JP. Genetic analysis of inherited hypertension in the rat. Physiol Rev. 2000;80:135-172.
5. Moreno C, Dumas P, Kaldunski ML, Tonellato PJ, Greene AS, Roman RJ, Cheng Q, Wang Z, Jacob HJ, Cowley AW Jr. Genomic map of cardiovascular phenotypes of hypertension in female Dahl S rats. Physiol Genomics. 2003;15:243-257.
6. Stoll M, Cowley AW Jr, Tonellato PJ, Greene AS, Kaldunski ML, Roman RJ, Dumas P, Schork NJ, Wang Z, Jacob HJ. A genomicsystems biology map for cardiovascular function. Science. 2001;294:1723-1726.
7. Dominiczak AF, Clark JS, Jeffs B, Anderson NH, Negrin CD, Lee WK, Brosnan MJ. Genetics of experimental hypertension. J Hypertens. 1998;16:1859-1869.
8. Pravenec M, Gauguier D, Schott J, Buard G, Kren V, Bila V, Szpirer C, Szpirer J, Wang JM, Huang H, St Lezin E, Spence MA, Flodman P, Printz M, Lathrop M, Vergnaud G, Kurtz TW. Mapping of quantitative trait loci for blood pressure and cardiac mass in the rat by genome scanning of recombinant inbred strains. J Clin Invest. 1995;96:1973-1978.
9. Deng AY. In search of hypertension genes in Dahl salt-sensitive rats. J Hypertens. 1998;16:1707-1717.
10. Rubattu S, Volpe M, Kreutz R, Ganten U, Ganten D, Lindpaintner K. Chromosomal mapping of quantitative trait loci contributing to stroke in a rat model of complex human disease. Nat Genet. 1996;13:429-434.
11. Siegel AK, Planert M, Rademacher S, Mehr AP, Kossmehl P, Wehland M, Stoll M, Kreutz R. Genetic loci contribute to the progression of vascular and cardiac hypertrophy in salt-sensitive spontaneous hypertension. Arterioscler Thromb Vasc Biol. 2003;23:1211-1217.
12. Siegel AK, Kossmehl P, Planert M, Schulz A, Wehland M, Stoll M, Bruijn JA, de Heer E, Kreutz R. Genetic linkage of albuminuria and renal injury in Dahl salt-sensitive rats on a high-salt diet: comparison with spontaneously hypertensive rats. Physiol Genomics. 2004;18:218-225.
13. Jeffs B, Clark JS, Anderson NH, Gratton J, Brosnan MJ, Gauguier D, Reid JL, Macrae IM, Dominiczak AF. Sensitivity to cerebral ischaemic insult in a rat model of stroke is determined by a single genetic locus. Nat Genet. 1997;16:364-367.
14. Glazier AM, Nadeau JH, Aitman TJ. Finding genes that underlie complex traits. Science. 2002;298:2345-2349.
15. Lifton RP. Genetic dissection of human blood pressure variation: common pathways from rare phenotypes. Harvey Lectures. 2004;100:71-101.
16. Bianchi G, Ferrari P, Staessen JA. Adducin polymorphism: detection and impact on hypertension and related disorders. Hypertension. 2005;45:331-340.
17. Rapp JP. A paradigm for identification of primary genetic causes of hypertension in rats. Hypertension. 1983;5(suppl I):I-198-I-203.
18. Cicila GT, Rapp JP, Wang J-M, St Lezin E, Ng SC, Kurtz TW. Linkage of 11 beta-hydroxylase mutations with altered steroid biosynthesis and blood pressure in the Dahl rat. Nat Genet. 1993;3:346-353.
19. Cicila GT, Garrett MR, Lee SJ, Liu J, Dene H, Rapp JP. High-resolution mapping of the blood pressure QTL on chromosome 7 using Dahl rat congenic strains. Genomics. 2001;72:51-60.
20. Garrett MR, Rapp JP. Defining the blood pressure QTL on chromosome 7 in Dahl rats by a 177-kb congenic segment containing Cyp11b1. Mamm Genome. 2003;14:268-273.
21. Matsukawa N, Nonaka Y, Higaki J, Nagano M, Mikami H, Ogihara T, Okamoto M. Dahl's salt-resistant normotensive rat has mutations in cytochrome P450(11B), but the salt-sensitive hypertensive rat does not. J Biol Chem. 1993;266:9117-9121.
22. Feldman D, Funder JW. The binding of 18-hydroxydeoxycoticosterone and 18-hydroxycorticosterone to minerlocortoid and glucocortoid receptors in the rat kidney. 1973;92:1389-1396.
23. Rapp JP, Tan SY, Margolius HS. Plasma mineralocorticoids, plasma renin, and urinary kallilrein in salt-sensitive and salt-resistant rats. Endocr Res Commun. 1978;5:35-41.
24. Nicholls MG, Brown WCB, Hay GD, Mason PA, Fraser R. Arterial levels and mineralocorticoid activity of 18-hydroxy-11-deoxycorticosterone in the rat. J Steroid Biochem. 1979;10:67-70.
25. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimeric 11B-hydroxylase/aldosterone synthase gene causes glucocorticoid- remediable aldosteronism and human hypertension. Nature. 1992;355:262-265.
26. Ferrari P, Ferrandi M, Valentini G, Manunta P, Bianchi G. Targeting ouabain- and adducin-dependent mechanisms of hypertension and cardiovascular remodeling as a novel pharmacological approach. Med Hypotheses. In press.
27. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
28. St-Onge M, Janssen I, Heymsfield SB. Metabolic syndrome in normalweight Americans. Diabetes Care. 2004;27:2222-2228.
29. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427-436.
30. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210-1214.
31. Mondon CE, Reaven GM. Evidence of abnormalities of insulin metabolism in rats with spontaneous hypertension. Metab Clin Exp. 1988;37:303-305.
32. Jacob H, Brown D, Bunker R, Daly M, Dzau V, Goodman A, Koike G, Kren V, Kurtz T, Lernmark A, Levan G, Mao Y, Pettersson A, Pravenec M, Simon J, Szpirer C, Szpirer J, Trolliet M, Winer E, Lander E. A genetic linkage map of the laboratory rat. Nat Genet. 1995;9:63-69.
33. Pravenec M, Gauguier D, Schott J, Buard G, Kren V, Bila V, Szpirer C, Szpirer J, Wang JM, Huang H, St Lezin EM, Spence MA, Flodman P, Printz M, Lathrop M, Vergnaud G, Kurtz TW. A genetic linkage map in the rat derived from recombinant inbred strains. Mamm Genome. 1996;7:117-127.
34. Pravenec M, Klir P, Kren V, Zicha J, Kunes J. An analysis of spontaneous hypertension in spontaneously hypertensive rats by means of new recombinant inbred strains. J Hypertens. 1989;7:217-222.
35. Steen RG, Kwitek-Black AE, Glenn C, Gullings-Handley J, Van Etten W, Atkinson OS, Appel D, Twigger S, Muir M, Mull T, Granados M, Kissebah M, Russo K, Crane R, Popp M, Peden M, Matise T, Brown DM, Lu J, Kingsmore S, Tonellato PJ, Rozen S, Slonim D, Young P, Knoblauch M, Provoost A, Ganten D, Colman SD, Rothberg J, Lander ES, Jacob HJ. A high-density integrated genetic linkage and radiation hybrid map of the laboratory rat. Genome Res. 1999;9:AP1-AP8.
36. Pravenec M, Zidek V, Simakova M, Kren V, Krenova D, Horky K, Jachymova M, Mikova B, Kazdova L, Aitman TJ, Churchill PC, Webb RC, Hingarh NH, Yang Y, Wang JM, Lezin EM, Kurtz TW. Genetics of Cd36 and the clustering of multiple cardiovascular risk factors in spontaneous hypertension. J Clin Invest. 1999;103:1651-1657.
37. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E, Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet. 1999;21:76-83.
38. Pravenec M, Landa V, Zidek V, Musilova A, Kren V, Kazdova L, Aitman TJ, Glazier AM, Ibrahimi A, Abumrad NA, Qi N, Wang JM, St Lezin EM, Kurtz TW. Transgenic rescue of defective Cd36 ameliorates insulin resistance in spontaneously hypertensive rats. Nat Genet. 2001;27:156-158.
39. Aitman TJ, Gotoda T, Evans AL, Imrie H, Heath KE, Trembling PM, Truman H, Wallace CA, Rahman A, Dor C, Flint J, Kren V, Zidek V, Kurtz TW, Pravenec M, Scott J. Quantitative trait loci for cellular defects in glucose and fatty acid metabolism in hypertensive rats. Nat Genet. 1997;16:197-201.
40. Bottger A, Van Lith HA, Kren V, Krenova D, Bila V, Vorlicek J, Zidek V, Musilova A, Zbodinska M, Wang JM, Van Zutphen BFM, Kurtz TW, Pravenec M. Quantitative trait loci influencing cholesterol and phospholipid phenotypes map to chromosomes that contain genes regulating blood pressure in the spontaneously hypertensive rat. J Clin Invest. 1996;98:856-862.
41. Pravenec M, Wallace C, Aitman TJ, Kurtz TW. Gene expression profiling in hypertension research: a critical perspective. Hypertension. 2003;41:3-8.
42. Hubner N, Wallace CA, Zimdahl H, Petretto E, Schulz H, Maciver F, Mueller M, Hummel O, Monti J, Zidek V, Musilova A, Kren V, Causton H, Game L, Born G, Schmidt S, Muller A, Cook SA, Kurtz TW, Whittaker J, Pravenec M, Aitman TJ. Integrated transcriptional profiling and linkage analysis for identification of genes underlying disease. Nat Genet. 2005;37:243-253.
43. Drake TA, Schadt EE, Davis RC, Lusis AJ. Integrating genetic and gene expression data to study the metabolic syndrome and diabetes in mice. Am J Therapeutics. 2005;12:503-511.
44. Abumrad NA, Elmaghrabi MR, Amri EZ, Lopez E, Grimaldi PA. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation-homology with human Cd36. J Biol Chem. 1993;268:17665-17668.
45. Hajri T, Ibrahimi A, Coburn CT, Knapp FF Jr, Kurtz TW, Pravenec M, Abumrad N. Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J Biol Chem. 2001;276:23661-23666.
46. Hajri T, Han XX, Bonen A, Abumrad NA. Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J Clin Invest. 2002;109:1381-1389.
47. Pravenec M, Zidek V, Landa V, Viklicky O, Sugimoto K, Qi N, Kurtz TW. Genetic variation in the renal expression of CD36 regulates blood pressure in the spontaneously hypertensive rat. Proceedings of the 21st Scientific Meeting of the International Society of Hypertension. 2006: Abstract 56.
48. Churchill PC, Churchill MC, Bidani AK, Kurtz TW. Kidney-specific chromosome transfer in genetic hypertension: the Dahl hypothesis revisited. Kidney Int. 2001;60:705-714.
49. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med. 2006;119(5 suppl 1):S10-S16.
50. Unger RH. The physiology of cellular liporegulation. Ann Rev Physiol. 2003;65:333-347.
51. Muoio DM, Newgard CB. Obesity-related derangements in metabolic regulation. Annu Rev Biochem. 2006;75:367-401.
52. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006;580:2917-2921.
53. Qi N, Kazdova L, Zidek V, Landa V, Kren V, Pershadsingh HA, Lezin ES, Abumrad NA, Pravenec M, Kurtz TW. Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone. J Biol Chem. 2002;277:48501-48507.
54. Goudriaan JR, Dahlmans VE, Teusink B, Ouwens DM, Febbraio M, Maassen JA, Romijn JA, Havekes LM, Voshol PJ. CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice. J Lipid Res. 2003;44:2270-2277.
55. Bezaire V, Bruce CR, Heigenhauser GJ, Tandon NN, Glatz JF, Luiken JJ, Bonen A, Spriet LL. Identification of fatty acid translocase on human skeletal muscle mitochondrial membranes: essential role in fatty acid oxidation. Am J Physiol Endocrinol Metab. 2006;290:E509-E515.
56. Pravenec M, Houstek J, Dudova K, Pecina P, Vrbacky M, Kazdova L, Wang J, Ho C, Qi N, Sugimoto K, Hyakukoku M, Kurtz TW. Mitochondrial genomics of the metabolic syndrome. Proceedings of the 21st Scientific Meeting of the International Society of Hypertension. 2006: Abstract 388.
57. Morino K, Petersen KF, Dufour S, Befroy D, Frattini J, Shatzkes N, Neschen S, White MF, Bilz S, Sono S, Pypaert M, Shulman GI. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest. 2005;115:3587-3593.
58. Bottger A, Lankhorst E, van Lith HA, van Zutphen LF, Zídek V, Musilová A, Simáková M, Poledne R, Bílá V, Kren V, Pravenec M. A genetic and correlation analysis of liver cholesterol concentration in rat recombinant inbred strains fed a high cholesterol diet. Biochem Biophys Res Commun. 1998;246:272-275.
59. Pravenec M, Jansa P, Kostka V, Zidek V, Kren V, Forejt J, Kurtz TW. Identification of a mutation in ADD1/SREBP-1 in the spontaneously hypertensive rat. Mamm Genome. 2001;12:295-298.
60. Qi NR, Wang J, Zidek V, Landa V, Mlejnek P, Kazdova L, Pravenec M, Kurtz TW. A new transgenic rat model of hepatic steatosis and the metabolic syndrome. Hypertension. 2005;45:1004-1011.
61. Davy KP, Hall JE. Obesity and hypertension: two epidemics or one. Am J Physiol Regul Integr Comp Physiol. 2004;286:R803-R813.
62. Kuo JJ, Jones OB, Hall JE. Chronic cardiovascular and renal actions of leptin during hyperinsulinemia. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1037-R1042.
63. Mark AL, Correia ML, Rahmouni K, Haynes WG. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens. 2002;20:1245-1250.
64. Zhu W, Smart EJ. Myristic acid stimulates endothelial nitric-oxide synthase in a CD36- and an AMP kinase-dependent manner. J Biol Chem. 2005;280:29543-29550.
65. Kincer JF, Uittenbogaard A, Dressman J, Guerin TM, Febbraio M, Guo L, Smart EJ. Hypercholesterolemia promotes a CD36-dependent and endothelial nitric-oxide synthase-mediated vascular dysfunction. J Biol Chem. 2002;277:23525-23533.
66. Miyaoka K, Kuwasako T, Hirano K, Nozaki S, Yamashita S, Matsuzawa Y. CD36 deficiency associated with insulin resistance. Lancet. 2001;357:686-687.
67. Hirano K, Kuwasako T, Nakagawa-Toyama Y, Janabi M, Yamashita S, Matsuzawa Y. Pathophysiology of human genetic CD36 deficiency. Trends Cardiovasc Med. 2003;13:136-141.
68. Corpeleijn E, van der Kallen CJ, Kruijshoop M, Magagnin MG, de Bruin TW, Feskens EJ, Saris WH, Blaak EE. Direct association of a promoter polymorphism in the CD36/FAT fatty acid transporter gene with Type 2 diabetes mellitus and insulin resistance. Diabet Med. 2006;23:907-911.
69. Ma X, Bacci S, Mlynarski W, Gottardo L, Soccio T, Menzaghi C, Iori E, Lager RA, Shroff AR, Gervino EV, Nesto RW, Johnstone MT, Abumrad NA, Avogaro A, Trischitta V, Doria A. A common haplotype at the CD36 locus is associated with high free fatty acid levels and increased cardiovascular risk in Caucasians. Hum Mol Genet. 2004;13:2197-2205.
70. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47:507-514.
71. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA, Ramachandran RK, Willson TM, Kliewer SA. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology. 2001;142:1269-1277.
72. Kurtz TW, Gardner DG. Transcription-modulating drugs-A new frontier in the treatment of essential hypertension. Hypertension. 1998;32:380-386.
73. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241-252.
74. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106-1118.
75. Kotchen TA. Attenuation of hypertension by insulin-sensitizing agents. Hypertension. 1996;28:219-223.
76. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-1105.
77. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials. 1998;19:217-231.
78. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880-883.
79. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256-263.
80. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR{gamma}-modulating activity. Hypertension. 2004;43:993-1002.
81. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109:2054-2057.
82. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens. 2004;22:2253-2261.
83. Janke J, Schupp M, Engeli S, Gorzelniak K, Boschmann M, Sauma L, Nystrom FH, Jordan J, Luft FC, Sharma AM. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J Hypertens. 2006;24:1809-1816.
84. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascular Pharmacol. 2006;45:154-162.
85. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U. Molecular characterization of new selective peroxisome proliferator-activated receptor {gamma} modulators with angiotensin receptor blocking activity. Diabetes. 2005;54:3442-3452.
86. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension. 2006;47:1003-1009.
87. Li YQ, Ji H, Zhang YH, Ding DY, Ye XL. Metabolic effects of telmisartan in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol. 2006;373:264-270.
88. Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in subjects with the metabolic syndrome. J Hypertens. In press.
89. Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, Rosano GM. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol. 2005;4:6-14.
90. Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, Oiso Y. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care. 2005;28:757-758.
91. Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan: Implications for treating insulin resistant hypertension and cardiovascular disease. Diabetes Care. 2004;27:1015.
92. Nagel JM, Tietz AB, Goke B, Parhofer KG. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism. 2006;55:1149-1154.
93. Benndorf RA, Rudolph T, Appel D, Schwedhelm E, Maas R, Schulze F, Silberhorn E, Boger RH. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism. 2006;55:1159-1164.
94. Kurtz TW. New treatment strategies for patients with hypertension and insulin resistance. Am J Med. 2006;119(5 suppl 1):S24-S30.
95. Michel MC, Bohner H, Koster J, Schafers R, Heemann U. Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Saf. 2004;27:335-344.
96. Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K, Elbrecht A, Johnson BA, Zhou G, Doebber TW, Biswas C, Parikh M, Sharma N, Tanen MR, Thompson GM, Ventre J, Adams AD, Mosley R, Surwit RS, Moller DE. Distinct properties and advantages of a novel peroxisome proliferator - activated protein {gamma} selective modulator. Mol Endocrinol. 2003;17:662-676.
97. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell. 2001;104:503-516.
98. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol. 2003;91:30H-37H.
99. Hsueh WA, Bruemmer D. Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension. 2004;43:297-305.
100. Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res. 2006;72:184-190.
101. Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K, Kanaide H, Takeshita A. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000;102:1834-1839.
102. Hattori Y, Akimoto K, Kasai K. The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II. Biochem Biophys Res Commun. 2000;273:1144-1149.
103. Goetze S, Xi XP, Graf K, Fleck E, Hsueh WA, Law RE. Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett. 1999;452:277-282.
104. Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascular Pharmacol. 2006;45:19-28.
105. Teo K, Yusuf S, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H. Rationale, design, and baseline characteristics of 2 large, simple randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Am Heart J. 2004;148:52-61.